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ORIGINAL ARTICLE
Causality Assessment of Cutaneous Adverse Drug 
Reactions
Young-Min Son, M.D., Jong-Rok Lee, M.D., Joo-Young Roh, M.D.
Department of Dermatology, Gachon University of Medicine and Science, Gil Hospital, Incheon, Korea
Background: Cutaneous adverse drug reactions (ADRs) are 
the most common adverse reactions attributed to drugs. A 
systematic and effective approach to a patient with suspected 
drug eruption allows for prompt recognition, classification 
and treatment of cutaneous ADRs. A standardized and 
effective approach for objective causality assessment is 
necessary to make consistent and accurate identification of 
ADRs. Objective: Although the Naranjo algorithm is the 
most widely used assessment tool, it contains many 
components which are not suitable for clinical assessment of 
ADRs in Korea. The purpose of this study is to compare 
correlations of the Naranjo algorithm and the Korean 
algorithm to evaluate usefulness of both algorithms in order 
to make a causal link between drugs and cutaneous ADRs. In 
addition, this study classifies the clinical types and causative 
agents of cutaneous ADRs. Methods:  The authors retro-
spectively reviewed the clinical types and laboratory 
findings of patients who were diagnosed with cutaneous 
ADRs in the dermatology clinic at Gil hospital. One hundred 
forty-one patients were enrolled in this evaluation. The 
causal relationship of ADRs was assessed by using the 
Naranjo algorithm and Korean algorithm (version 2.0). 
Results: A cross-tabulation analysis was applied to the 
Naranjo algorithm and Korean algorithm (version 2.0). 
Simple correlation analysis and a Bland-Altman plot were 
used for statistical analysis. Correlation analysis confirmed 
that the two assessment algorithms were significantly 
correlated. Exanthematous eruptions (68.8%), Stevens- 
Johnson syndrome (10.6%), and urticaria (8.5%) were the 
most common types of cutaneoues ADRs. The most 
common causative agents were antibiotics/antimicrobials, 
antipyretics/non-steroidal anti-inflammatory drugs, and cen-
tral nervous system depressants. Conclusion: The Naranjo 
algorithm and Korean algorithm (version 2.0) were signifi-
cantly correlated with each other, and thus reliable assess-
ment methods to determine cutaneous ADRs. (Ann Derma-
tol 23(4) 432∼438, 2011)
-Keywords-
Cutaneous adverse drug reactions, Korean algorithm, Na-
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INTRODUCTION
Cutaneous adverse drug reactions (ADRs) are defined as 
noxious, unintended, morphologic skin changes, with or 
without systemic involvement, that develop after local or 
systemic administration of drugs in dosages commonly 
used for prevention, diagnosis, or treatment of diseases or 
modification of physiologic functions
1-3. There is a wide 
spectrum of cutaneous ADRs, varying from transient mac-
ulopapular rashes to fatal toxic epidermal necrolysis
4,5. 
The pattern of cutaneous ADRs and the drugs responsible 
for the ADRs change every year.
Most cutaneous ADRs are mild, self-limited, and usually 
resolve after the offending agent has been discontinued, 
but some severe cutaneous reactions may result in serious 
morbidity, and even death
6-9. Since quick and careful at-
tention to the diagnosis and treatment of cutaneous ADRs 
is required, a standardized approach is necessary to estab-
lish a final decision of causality to result in a consistent, Causality Assessment of Cutaneous Adverse Drug Reactions
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 1. Previous report?  ＋1  0    0   −
 2. Event after drug?  ＋2 −1   0  −
 3. Event abate on drug removal?  ＋1  0    0   −
 4. ＋Re-challenge?   ＋2 −1   0  −
 5. Alternative causes?  −1 ＋2   0  −
 6. Reaction with placebo?  −1 ＋1   0  −
 7. Drug blood level toxic?  ＋1  0    0   −
 8. Reaction dose-related?  ＋1  0    0   −
 9. Past history of similar event?  ＋1  0    0   −
10. ADR confirmed objectively?  ＋1  0    0   −
ADR: adverse drug reaction.
Table 1. Age and sex distribution 
Age (years) Male Female Total %
  0 ∼10  5  3   8  5.7
 11∼20  5  3   8  5.7
 21∼30  7 11  18 12.8
 31∼40  7 12  19 13.5
 41∼50 12 21  33 23.4
 51∼60  9 17  26 18.4
 61∼70  8  8  16 11.3
 71∼80  7  1   8  5.7
 81~90  3  2   5  3.5
  Total 63 78 141
   % 44.7 55.3 100
accurate and reproducible identification of ADRs. 
In Korea, many types of drugs are prescribed at the same 
time and people take oriental medicines frequently
10,11. 
During the past few years, as more new drugs have been 
produced, cutaneous reactions have occurred more 
frequently. Further, established drugs have also been re-
ported to cause new eruptions not previously reported
10-12.
This study was designed to survey the cutaneous ADRs 
amongst patients who visited a particular dermatologic 
clinic during the past three year period and to compare 
the accuracy of the Naranjo
13 algorithm and Korean 
algorithm (version 2.0)
14 to evaluate causal association 
between drugs and cutaneous ADRs.
MATERIALS AND METHODS
Materials
The authors examined 141 patients with cutaneous ADRs 
who attended the dermatology clinic at Gil hospital from 
January 2006 till December 2008. Mean age was 45 years 
(range, 1∼90 years) and the majority of the patients 
belonged to the 41∼50 year age group, followed by the 
51∼60 and 31∼40 year age groups. Sixty-three patients 
(44.7%) were males and 78 patients (55.3%) were females 
(Table 1).
Methods
The diagnosis of cutaneous ADRs was primarily based on 
detailed histories and the correlation between drug intake 
and the onset of the ADR. The diagnosis was confirmed 
by observing the resolution of signs and symptoms after 
discontinuation of the suspected offending drugs. Medical 
histories and physical examinations were performed by 
one of the authors. A careful history of symptoms, other 
skin and systemic diseases, medical history, and a family 
history of drug eruptions or any other disease was 
obtained. A thorough clinical examination was carried 
out. The skin, hair, nails, and mucosa (eyes, oral, and 
genital) were examined. Complete blood cell counts, liver 
function tests, and renal function tests were carried out.
Assessment of ADRs
Each case was assessed for its causality using the Naranjo 
algorithm
13 (Table 2) and Korean algorithm (version 2.0)
14 
(Table 3). The Naranjo algorithm consists of ten questions 
and is scored as follows: scores of 9 or 10 indicate that an 
event is ‘definitely’ an ADR, scores of 5∼8 rate the 
likelihood of an ADR as ‘probable’, scores of 1∼4 are 
‘possible’ ADRs, and scores of less than 1 are ‘doubtful’ 
ADRs
13. The Korean algorithm (version 2.0) consists of 
eight questions with scores as follows: greater than 9 is 
‘certain’ for an ADR, 6∼8 is ‘probable/likely’ for an ADR, 
3∼5 is ‘possible’ for an ADR, 1∼2 is ‘unlikely’ for an 
ADR, and less than 0 is ‘contradictory’ for an ADR
14.
Statistics
Statistical Package for the Social Sciences (SPSS, SPSS Inc., 
Chicago, IL, USA) 12.0 was used for comparative analysis 
on the Naranjo algorithm and Korean algorithm (version 
2.0). To assess the correlation between the two values, a 
simple correlation analysis, Pearson’s simple correlation 
coefficient, and intra-class correlation coefficient (ICC) 
were used. A Bland-Altman plot was used to assess the 
reliability of the two values.
RESULTS
Assessment of causal association
Cross-tabulation analysis was performed to assess the 
correlation and reliability of the Naranjo algorithm and 
Korean algorithm (version 2.0) (Table 4). Simple cor-
relation analysis yielded a Pearson’s simple correlation YM Son, et al
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Table 3. Prototype of Korean algorithm for ADR causality assessment (ver. 2.0)
Items Questions Answers Assessment (score) Remark
Chronologic 
relationship






Yes Appropriate chronologic relationship (+3)













Clinical response after dose reduction (+3)
Clinical progress irrespective of the dose reduction, 
stop was seen (−2)
Dose reduction or removal of suspected drug 







Past history of 
ADR
Have you ever 
experienced ADR 




No information  (0)
Combined 
medication
Is there any 
information of the 
drugs being taken 
in combination?
Yes In case the ADR can’t be caused by the drug 
used in combination (+2)
　
In case the drug used in combination alone can 
cause ADR (−3)
In case data are available by interaction with 
suspicious drug (+2)








Yes ADR can’t be provocated by non-drug cause (+1) 　





Indicated in the permission materials 
(label, insert, etc.) (+3)
Not indicated, but there existed case reports (+2)
Unknown (0)
　
Re-challenge Is there any 
information of re- 
challenge?
Yes Similar response to re-challenge (+3)




Specific tests Specific tests such as 
provocation tests, 







Total (highest point 19∼l o w e s t  p o i n t s  - 1 3 )  :                                                           p o i n t s
ADR: adverse drug reaction.
Table 4. Naranjo and Korean algorithm v 2.0 cross tabulation




Naranjo Possible   5 29 5 39
 algorithm Probable 0 32 70 102
Total 5 61 75 141
coefficient of 0.682 (p-value=0.0) (Fig. 1), and the 
measurement of inter-rater reliability by ICC was 0.67 
(0.57∼0.75), which ascertains a signific ant correlation of 
the measured quantitative values of the two assessments. 
A Bland- Altman plot graph was used to determine if a 
difference existed between the measured quantitative 
values of the two assessments. The analysis showed that 
the values were widely spread on the x-axis, revealing the 
existence of various test variables, which indicates tha t 
the test was properly conducted. In addition, most values 
were distributed within ＋/− one standard variation, sug-
gesting that the reliability between the two assessments 
was high (Fig. 2). The difference in the two values became 
greater in inverse proportion to the average, thus low 
scores required more scrutiny.Causality Assessment of Cutaneous Adverse Drug Reactions
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Fig. 2. The x-axis indicates the average of the two values, and
the y-axis indicates the difference of the two values, being diffuse
sideward means there are many experimental variables. The 
up-and-down lines in the graph mean a ＋/−1 standard 
variation, and the more the measured quantity values are within
the two lines, the higher the reliability.
Fig. 1. The measured quantity values of the Korean algorithm
(version 2.0) in the x-axis and the Naranjo algorithm in the y-axis
are significantly correlated.
Table 7. Causative antibiotics & antimicrobials
Drugs No. of patient %
  Penicilin group 　12 25.0
  Cephalosporin group (Gen I) 　24 . 2
  Cephalosporin group (Gen II) 　48 . 3
  Cephalosporin group (Gen III) 　5 10.4
  Quinolone 8 16.6
  Antifungal agents 　6 12.5
  Antituberculous group 　5 10.4
  Macrolide group 　24 . 2
  Tetracycline 　12 . 1
  Aminoglycoside group 1 2.1
  O t h e r s 　24 . 2
  Total 48 100
Table 5. Clinical types of drug eruption
Clinical type No. of patients %
  Exanthematous eruption 　　　　97 68.8
  Stevens-Johnson syndrome 　　15 10.6
  Urticaria 　　　　12  8.5
  Erythema multiforme 9  6.4
  Fixed drug eruption 4  2.9
  Toxic epidermal necrolysis 2  1.4
  Bullous eruption 1  0.7
  Pustular eruption 1  0.7
  Total 141    100.0
Table 6. Agents responsible for eruptions
Agents No. of patients %
  Antibiotics/antimicrobials 48 34.1
  Antipyretics/NSAIDs 38 27.0
  CNS depressants 17 12.1
  Anticancer agents 10  7.1
  Radiographic dye  5  3.6
  Gout preparation  4  2.8
  H e r b  4  2 . 8
  GIT regulators/antacid agents  4  2.8
  Antihypertensive drug  3  2.1
  Antihemorrhagic agents  2  1.4
  Diuretics  2  1.4
  Others  4  2.8
  Total 141  100.0
NSAIDs: non-steroidal anti-inflammatory drugs, CNS: central 
nervous system, GIT: gastrointestinal tract.
Clinical features & latent period
The cutaneous manifestations of ADRs in the order of 
frequency were as follows: exanthematous eruption, 97 
(68.8%); Stevens-Johnson syndrome, 15 (10.6%); urticaria, 
12 (8.5%); erythema multiforme, 9 (6.4%); fixed drug 
eruption, 4 (2.9%); toxic epidermal necrolysis, 2 (1.4%); 
bullous eruption, 1 (0.7%) and pustular eruption, 1 (0.7%) 
(Table 5).
The interval between the time the medication was 
administered and the clinical appearance of the ADR was 
‘less than a week’ in 57 cases (40.4%), ‘less than 24 
hours’ in 38 cases (27%), and ‘after four weeks’ in 17 
cases (5%). Thirty of 48 cases (62.5%) caused by 
antibiotics/antimicrobials developed ADRs within one 
week, and 13 cases (27.1%) developed ADRs within a 
day. Five cases caused by radiographic dye developed 
within a day.
Causative agents
The precise history of ADR, including allopathic, ho-YM Son, et al
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Table 8. Comparison of four reports on cutnaeous ADRs
Reference No. of patient Highest incidence Clinical types Causative agents
  Kim and Lee
12   211 male
  213 female
21 to 30 yrs    Exanthematous eruption (47.6%),
   Fxed drug eruption (25.7%),
   Urticaria (12.1%)
   Antibiotics (40.4%),
   Antipyretics/NSAID (23.5%),
   Others (herb) (12.5%)
  Shin et al.
11    64 male
   63 female
21 to 30 yrs    Exanthematous eruption (37.8%),
   Urticaria (28.3%),
   Erythema multiforme (11.1%)
   Antibiotics (44.2%),
   Antipyretics/NSAID (29.5%),
   CNS depressants (16.8%)
  Kim et al.
10   147 male
  123 female
31 to 40 yrs    Exanthematous eruption (49.3%),
   Fixed drug eruption (30.1%),
   Urticaria (10.0%)
   Antibiotics (46.3%),
   Antipyretics/NSAID (32.2%),
   CNS depressants (6.3%)
  Our study    63 male
   78 female
41 to 50 yrs    Exanthematous eruption (68.8%),
   Stevens-Johnson syndrome (10.6%),
   Urticaria (8.5%)
   Antibiotics (34.1%),
   Antipyretics/NSAIDs (27.0%),
   CNS depressants (12.1%)
ADR: adverse drug reaction, NSAIDs: non-steroidal anti-inflammatory drugs, CNS: central nervous system.
meopathic, and herbal remedies and self-medication was 
obtained from patients with cutaneous ADRs, and the 
imputability of each drug as a possible culprit was deter-
mined. The most common causative agents were anti-
biotics/antimicrobials (34.1%), followed by antipyretics/ 
NSAIDs (27.0%), CNS depressants (12.1%), and anti-
cancer drugs (7.1%) (Table 6). 
Among the antibiotics/antimicrobials, penicillins and ce-
phalosporins were responsible for causing the majority of 
cutaneous ADRs; amoxicillin was the most common 
causative antibiotics (Table 7). Five cases of cutaneous 
ADRs were caused by iodide, which is used for computer 
tomography, intravenous pyelography, and myelography. 
The other causative agents were allopurinol, herbs, 
antihypertensive drugs, and gastrointestinal tract regulators/ 
antacids (Table 6).
Laboratory findings
Liver function abnormalities, eosinophilia, and leuko-
cytosis were present in 36.0% (31/86), 33.7% (29/86), and 
15.1% of the patients (13/86), respectively. Leukocytosis 
was commonly present in patients with Stevens-Johnson 
syndrome and exanthematous eruption; liver function 
abnormalities were commonly present in patients with 
exanthematous eruptions, Stevens-Johnson syndrome, and 
erythema multiforme, but no cases of toxic hepatitis 
occurred.
Associated signs and symptoms
The major presenting complaint was itching (61.0%), 
followed by fever (9.2%) and myalgia (6.4%). Other 
symptoms included oral mucosal lesions (5.0%), including 
cheilitis, stomatitis, facial edema (2.8%), and gas-
trointestinal symptoms, such as diarrhea and vomitting 
(0.7%).
DISCUSSION
Two to three percent of hospitalized medical patients are 
reported to have cutaneous ADRs
15-17. Fatal cutaneous 
ADRs occur in 0.1% of medical patients and 0.01% of sur-
gical patients
15-17.
There are five reports on the incidence of cutaneous ADRs 
ranged from 2.6% to 8.9% assessed by dermatologist in 
Korea
10-12,18,19. Kim and Lee
12 and Bang et al.
18 reported 
that 2.7% and 3.8% of patients visited hospitals because 
of cutaneous ADRs, respectively, and Shin et al.
11 re-
ported that 8.9% of inpatients had cutaneous ADRs. 
Hahm
19 reported that 2.6% of inpatients with dermatology 
consultations were diagnosed with cutaneous ADRs. 
According to the report by Kim et al.
10, the incidence of 
cutaneous ADRs was 1.32% in the 1970s, 1.33% in the 
1980s, and 1.78% in 1990s; the gradual increase in the 
incidence of ADRs has been attributed to diversification, 
abuse, and misuse of drugs. However, the incidence and 
type of cutaneous ADRs evaluated by dermatologist in 
2000’s has not been reported on. As the incidence of 
ADRs is increasing, people perceive ADRs with greater 
concern. Proper monitoring systems and causality assess-
ment are required to prevent the severe cutaneous ADRs 
which cause death, threaten lives, affect fetuses, and lead 
to permanent disability
20,21. Recently, an ADR monitoring 
system (pharmacovigilance research network) has been 
activated in Korea. Since cutaneous ADRs are the most 
common, it is highly desirable for dermatologist to ac-
tively participate in the network.
The algorithms for causality assessment that are widely 
used in foreign nations include the Naranjo algorithm
13, 
the French algorithm
22, and the RUCAM algorithm
23. 
These algorithms are used in foreign countries with differ-
ent genetic backgrounds, investigators, and level of aware-Causality Assessment of Cutaneous Adverse Drug Reactions
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ness for ADRs, and as such they might not suitable for use 
in Korea
12,14,22. The Naranjo algorithm, which was estab-
lished in 1981, is the most widely used assessment tool 
and consists of ten simple questions
13. The merits of the 
Naranjo algorithm are that it is easy to apply, and assess-
ment is possible with very little information and knowl-
edge
13,14. The downside of the Naranjo algorithm is the 
absence of a time-related detailed description (question 2), 
assessment for the response after administering a placebo 
that actually had not been carried out (question 6), and a 
non-concrete question (question 10), which may cause dif-
ferences between investigators
13,14,21. In fact, there was 
much difference between the researchers in studies under-
taken to determine the causality assessment for ADRs of 
inpatients
24,25. Similarly, the Naranjo algorithm contains 
many components that are not suitable for clinical assess-
ment for ADRs in Korea and, when applied, the scores are 
mostly evaluated as ‘probable’. Specifically, 102 cases 
(72.3%) were assessed as ‘probable’ in the current study. 
Ultimately, Hong et al.
14 developed the Korean algorithm, 
and improved ambiguous descriptions of the clinical 
course by adding proportional dose-dependent responses, 
event abatement, and clinical appearance on drug re-
moval
14,21,23. Some questions were specialized for consis-
tent assessment as the period between administration and 
symptom onset, risk factors, and drug- unrelated factors
14. 
Finally, the Korean algorithm (version 2.0) was developed 
as the assessment of the causal association between the 
suspected drug and the cutaneous ADR, which can be 
properly applied to Koreans. The Korean algorithms 
(version 2.0) will be helpful for clinical use as items with a 
low response rate in Korea were excluded.
The correlation and reliability of the Naranjo and Korean 
algorithms (version 2.0) were assessed and analyzed in 
this study and it was found that the Korean algorithm 
(version 2.0) was significantly correlated with the Naranjo 
algorithm. The result of cross-tabulation analysis showed 
that 102 cases which were assessed as ‘probable’ based 
on the Naranjo algorithm were separated into ‘pro-
bable/likely’ and ‘certain’, and 39 cases assessed as 
‘possible’ were separated into ‘possible’, ‘probable/likely’, 
and ‘certain’ (Table 4). Thus, these findings indicate that 
the Korean algorithm (version 2.0) can be used more prop-
erly in ascertaining risk factors earlier and reflecting 
prognosis.
There was no significant difference in the incidence of 
ADRs between men and women, which is in agreement 
with the results of the other studies (Table 8). ADRs in-
crease with age, which may be due to the increased use of 
medications by the elderly, the increased potential for 
drug-drug interactions, and altered drug metabolism by 
the body. The majority of the patients belonged to the 41
∼50 year age group in our study, the 21∼30 year age 
group in the studies by Kim and Lee
12  and Shin et al.
11, 
and the 31∼40 year age group in a study by Kim et al.
10, 
respectively (Table 8).
The difference in various studies may be related to the re-
gional variation in the health care-seeking behavior of the 
population.
The clinical types of cutaneous ADRs are classified into 
exanthematous eruption, urticaria, photosensitivity reac-
tion, erythema multiforme, Stevens-Johnson syndrome, 
toxic epidermal necrolysis, fixed drug eruption, purpura, 
lichenoid eruption, and bullous eruption
1-3. 
Of patients with ADRs, Kim et al.
10 reported exan-
thematous eruptions in 49.3%, fixed drug eruptions in 
30.1%, and urticaria in 10.1% as the most common pat-
terns of eruptions. Of the various types of cutaneous ADRs 
seen in the current study, exthanthematous eruptions were 
the most common drug eruptions (68.8%), followed by 
Stevens-Johnson syndrome (10.6%) and urticaria (8.50%). 
The most common latent period for cutaneous ADRs was 
1∼7 days, which corresponds with the symptom onset of 
exanthematous eruption, the most common clinical type 
of ADR. 
The frequency of clinical types and causative agents were 
determined for outpatients by Kim and Lee
12 between 
1969 and 1975, for inpatients by Shin et al.
11 between 
1976 and 1985, and for outpatients and inpatients by Kim 
et al.
10 between 1989 and 1997. When compared to the 
present study, the most common causative agent for ADRs 
was salicylate in a study by Kim and Lee
12, ampicillin in a 
study by Shin et al.
11, amoxicillin in a study by Kim et 
al.
10, and amoxicillin in the present study (Table 8).
In the order of frequency of clinical types of ADR, there 
were differences between the reports (Table 8). The in-
cidence of life-threatening cutaneous ADRs, such as 
Stevens-Johnson syndrome, was higher compared to stud-
ies reported in Korea and internationally, which may rep-
resent that those patients with severe reactions visited the 
hospital in question more often. Allopurinol was a com-
mon cause of Stevens-Johnson syndrome in this survey.
Leukocytosis, eosinophilia and liver function abnormal-
ities are often observed in patients with ADRs
26-28. Of pa-
tients with ADRs, Shin et al.
11 reported 42.0% had leuko-
cytosis, 29.5% had eosinophilia, and 25.3% had liver 
function abnormalities; the corresponding abnormalities 
in laboratory findings in the present study were 15.1%, 
33.7%, and 36.0%, respectively.YM Son, et al
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CONCLUSION
The Korean algorithm (version 2.0) was significantly 
correlated with the Naranjo algorithm and reflects 
prognosis properly when assessing Korean cutaneous 
ADRs. The findings of this study indicate that the Korean 
algorithm (version 2.0) can be used more properly than 
the Naranjo algorithm in ascertaining risk factors earlier 
and reflecting prognosis. Objective and consistent 
causality assessment is continuously required to detect the 
correlation of clinical index and cutaneous ADRs.
The clinical spectrum and causative agents of ADRs were 
similar to studies reported in Korea and internationally 
with minor variations. A wide clinical spectrum of 
cutaneous ADRs, ranging from mild maculopapular rash 
to serious Stevens-Johnson syndrome and toxic epidermal 
necrolysis were observed. The most common reaction 
pattern was an exanthematous eruption and the most 
frequent eliciting drug group was the antibiotics. Present 
findings on the most common reactions and eliciting 
drugs are in agreement with previous reports.
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